We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$26M
(-12%)
Cap. Flow
-$20.8M
Cap. Flow
% of AUM
-10.75%
Top 10 Holdings %
Top 10 Hldgs %
57.01%
Holding
46
New
13
Increased
3
Reduced
13
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adaptive Biotechnologies
ADPT
|
+$15.6M |
| 2 |
Sotera Health
SHC
|
+$12.4M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$11.8M |
| 4 |
AstraZeneca
AZN
|
+$11M |
| 5 |
UnitedHealth
UNH
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$21.2M |
| 2 |
Standard BioTools
LAB
|
+$9.27M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$8.36M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$7.73M |
| 5 |
Codexis
CDXS
|
+$6.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Jazz Pharmaceuticals
JAZZ
$16.2B
| $12.2M | 6.31% |
74,164
-15,725
| -17% | -$2.59M |
|
|
2
Sotera Health
SHC
$5.09B
| $11.7M | 6.03% |
+467,277
| New | +$12.4M |
|
|
3
Adaptive Biotechnologies
ADPT
$3.87B
| $11.6M | 5.99% |
+287,490
| New | +$15.6M |
|
|
4
Vertex Pharmaceuticals
VRTX
$122B
| $11.6M | 5.99% |
+53,855
| New | +$11.8M |
|
|
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.3M | 5.86% |
163,135
+61,890
| +61% | +$4.76M |
|
6
Insulet
PODD
$11.5B
| $11.3M | 5.83% |
43,183
-2,441
| -5% | -$654K |
|
|
7
UnitedHealth
UNH
$383B
| $10.9M | 5.65% |
+29,357
| New | +$10.2M |
|
|
8
AstraZeneca
AZN
$266B
| $10.9M | 5.63% |
+109,459
| New | +$11M |
|
9
Guardant Health
GH
$20.2B
| $9.45M | 4.89% |
61,909
-17,330
| -22% | -$2.62M |
|
|
NSTG
10
DELISTED
NanoString Technologies, Inc.
NSTG
| $9.37M | 4.85% |
142,530
-30,332
| -18% | -$2.13M |
|
11
Biodesix
BDSX
$221M
| $9.02M | 4.67% |
22,203
-1,746
| -7% | -$780K |
|
|
EPIX
12
DELISTED
ESSA Pharma
EPIX
| $8.26M | 4.27% |
+284,459
| New | +$6.61M |
|
13
Kura Oncology
KURA
$826M
| $7.84M | 4.06% |
277,468
-69,050
| -20% | -$2.18M |
|
14
Arcus Biosciences
RCUS
$3.55B
| $6.64M | 3.44% |
236,494
-111,914
| -32% | -$3.89M |
|
|
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.44M | 3.33% |
712,371
-243,485
| -25% | -$1.97M |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $5.96M | 3.08% |
79,650
-102,000
| -56% | -$8.36M |
|
|
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $5.35M | 2.77% |
+520,858
| New | +$5.7M |
|
|
ASLN
18
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $4.53M | 2.34% |
+33,814
| New | +$4.28M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.16M | 2.15% |
+24,263
| New | +$4.8M |
|
|
RNLX
20
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $4.13M | 2.14% |
+160,969
| New | +$4.03M |
|
21
PMV Pharmaceuticals
PMVP
$60.3M
| $3.88M | 2.01% |
118,128
+21,533
| +22% | +$849K |
|
|
MREO
22
Mereo BioPharma
MREO
$50.3M
| $3.58M | 1.85% |
1,063,264
+323,452
| +44% | +$1.14M |
|
|
ITOS
23
DELISTED
iTeos Therapeutics
ITOS
| $3.5M | 1.81% |
102,286
-36,098
| -26% | -$1.3M |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $3.1M | 1.6% |
+198,547
| New | +$2.94M |
|
|
SEEL
25
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $2.2M | 1.14% |
+115
| New | +$1.34M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Asymmetry Capital Management held 46 positions worth $193M, down 12% from $219M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Asymmetry Capital Management withdrew a net $20.8M in Q1 2021, closing 17 positions and reducing 13 holdings. Its most notable exit was Viatris, an estimated $21.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.
Against the trend, Asymmetry Capital Management opened a new position in Adaptive Biotechnologies worth $11.6M.
- Asymmetry Capital Management's largest Q1 2021 buy was Adaptive Biotechnologies: 287,490 shares worth $11.6M.
- Asymmetry Capital Management added most to Arena Pharmaceuticals Inc in Q1 2021, an estimated $4.76M increase.
- Asymmetry Capital Management's biggest Q1 2021 reduction was Sage Therapeutics, cutting an estimated $8.36M.
- Asymmetry Capital Management fully exited Viatris in Q1 2021, selling an estimated $21.2M.
- Asymmetry Capital Management's ten largest holdings make up 57% of its $193M portfolio in Q1 2021.
- Asymmetry Capital Management opened 13 new positions and closed 17 in Q1 2021.
- Asymmetry Capital Management's portfolio value fell 12% quarter-over-quarter to $193M.
Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.